BRCA1 and neoplasm: Interrogating tumour DNA for gene-specific loss of heterozygosity in germline carriers of non-BRCA1/2 HRR pathogenic variants may help to clarify whether borderline GIS-negative tumours have biallelic inactivation and are more likely to respond to PARPi [52].